Viewing Study NCT02041260

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:09 AM
Ignite Modification Date: 2026-02-25 @ 7:03 PM
Study NCT ID: NCT02041260
Status: UNKNOWN
Last Update Posted: 2021-10-15
First Post: 2014-01-17
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting
Sponsor: Thomas Jefferson University
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Poorly Differentiated Thyroid Cancer View
None Differentiated Thyroid Cancer (DTC) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Adult View
None differentiated thyroid cancer (DTC), View
None poorly differentiated thyroid cancer View
None not anaplastic thyroid cancer View